5.4% Less Acorda Therapeutics Inc (NASDAQ:ACOR) Shorted Shares

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Corporate Logo

Big Money Sentiment increased to 1.45 in Q2 2018. It has change of 0.02, from 2018Q1’s 1.43. The ratio increased due to Acorda Therapeutics, Inc. positioning: 16 sold and 46 reduced. 34 funds amassed positions and 56 increased positions. Investors holded 48.53 million in 2018Q1 but now own 47.68 million shares or 1.76% less.
Alps stated it has 51,801 shs or 0.01% of all its holdings. State Of Wisconsin Board holds 44,400 shs or 0% of its capital. Los Angeles Capital Mngmt Equity Rech Inc invested in 0% or 16,400 shs. Element Capital Mngmt Limited Liability Company, New York-based fund reported 22,853 shs. 100 were accumulated by Ima Wealth. Commonwealth Of Pennsylvania Pub School Empls Retrmt System has 9,956 shs. Malaga Cove Ltd reported 52,163 shs stake. Aperio Grp Ltd Liability Co owns 14,137 shs or 0% of their US capital. Matarin Cap Mgmt Lc holds 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR) or 160,810 shs. Dekabank Deutsche Girozentrale reported 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Arrowstreet Cap Partnership owns 27,036 shs. Gotham Asset Management Limited Company owns 42,938 shs. Mutual Of America Management Ltd Liability Com owns 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 173 shs. Daiwa Securities Group Inc Inc Inc holds 258 shs or 0% of its capital. Qs Invsts Ltd Co invested in 0.03% or 101,989 shs.

Acorda Therapeutics, Inc. registered $45.28 million net activity with 0 buys and 17 sales since June 7, 2018. On Thursday, June 28 the insider Sabella Lauren M sold $163,140. Shares for $2.48M were sold by SCOPIA CAPITAL MANAGEMENT LP on Monday, July 23. 25,000 Acorda Therapeutics, Inc. (NASDAQ:ACOR) shs with value of $704,783 were sold by LAWRENCE DAVID. 25,000 shs were sold by SMITH IAN F, worth $785,568 on Friday, June 15. On Monday, November 26 Randall Lorin had sold 1,904 shs worth $38,034.

Acorda Therapeutics Inc (NASDAQ:ACOR) recorded a decrease of 5.4% in shorted shares. It was announced in December by FINRA the 4.26 million shorted shares on ACOR. The 4.50 million previous shares are down with 5.4%. 14 days will cost ACOR with 313,400 average volume to restore its former position. Acorda Therapeutics Inc float short is 10.84%.

Ticker’s shares touched $18.63 during the last trading session after 0.96% change.Currently Acorda Therapeutics, Inc. is downtrending after 20.26% change in last December 8, 2017. ACOR has also 686,334 shares volume. The stock underperformed the S&P500 by 35.88%.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States.The firm is valued at $886.01 million. The firm markets Ampyra , an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.Currently it has negative earnings. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Coverage

In total 3 analysts cover Acorda Therapeutics (NASDAQ:ACOR). “Buy” rating has 1, “Sell” are 0, while 2 are “Hold”. 33% are bullish. 4 are the (NASDAQ:ACOR)’s analyst reports since June 11, 2018 according to StockzIntelligence Inc. On Tuesday, August 7 the stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) earned “Hold” rating by Stifel Nicolaus. On Friday, October 5 the company was maintained by Stifel Nicolaus. In Monday, June 11 report H.C. Wainwright maintained it with “Buy” rating and $3100 target.

For more Acorda Therapeutics, Inc. (NASDAQ:ACOR) news published briefly go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Benzinga.com or Nasdaq.com. The titles are as follows: “Premarket analyst action – healthcare – Seeking Alpha” published on August 23, 2018, “Acorda working through Ampyra patent infringement cases – Seeking Alpha” on August 03, 2018, “Detailed Research: Economic Perspectives on KB Home, Lennox International, CorVel, Acorda Therapeutics, PROS, and AMAG Pharmaceuticals — What Drives Growth in Today’s Competitive Landscape – Nasdaq” with a publish date: November 08, 2018, “24 Stocks Moving In Friday’s Mid-Day Session – Benzinga” and the last “Acorda Down More Than 30% in the Past 3 Months: Here’s Why – Nasdaq” with publication date: November 15, 2018.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.